European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Sökning: id:"swepub:oai:DiVA.org:liu-193227" > European experts co...

1 av 1
Föregående post
Nästa post
Till träfflistan

European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer

Vergote, I. (författare): Division of Gynaecological Oncology, Department of Gynaecology and Obstetrics and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium

González-Martín, A. (författare): Clinica Universidad de Navarra, Madrid, Spain; Program for Solid Tumors at Centro de Investigación Médica Aplicada (CIMA), Pamplona, Spain

Ray-Coquard, I. (författare): Medical Oncology, Centre Leon Bérard and Université Claude Bernard Lyon, Lyon, France

visa fler...

Harter, P. (författare): Department of Gynaecology & Gynaecologic Oncology, Ev. Kliniken Essen-Mitte, Essen, Germany

Colombo, N. (författare): University of Milan-Bicocca and European Institute of Oncology IRCCS, Milan, Italy

Pujol, P. (författare): Montpellier Faculty of Medicine, University Hospital of Montpellier, Montpellier, France

Lorusso, D. (författare): Department of Women and Child Science and Public Health, Catholic University of Rome, Fondazione Policlinico Gemelli IRCCS, Rome, Italy

Mirza, M.R. (författare): Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

Brasiuniene, B. (författare): Department of Medical Oncology, National Cancer Institute of Lithuania, Faculty of Medicine of Vilnius University, Vilnius, Lithuania

Madry, R. (författare): Oncological Gynaecology Department, Poznan University of Medical Sciences, Poznan, Poland

Brenton, J.D. (författare): Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK

Ausems, M.G.E.M. (författare): Division Laboratories, Pharmacy and Biomedical Genetics, Department of Genetics, University Medical Center Utrecht, Utrecht, The Netherlands

Büttner, R. (författare): Institute of Pathology, University Hospital Cologne, Cologne, Germany

Lambrechts, D. (författare): Department of Human Genetics, VIB and KU Leuven, Leuven, Belgium

visa färre...

(creator_code:org_t)

Elsevier BV, 2022
2022
Engelska.
Ingår i: Annals of Oncology. - : Elsevier BV. - 0923-7534 .- 1569-8041. ; 33:3, s. 276-287

Relaterad länk:: https://liu.diva-por... (primary) (Raw object); visa fler...; http://www.annalsofo...; https://urn.kb.se/re...; https://doi.org/10.1...; visa färre...

Forskningsöversikt (refereegranskat)

Abstract Ämnesord

Stäng

Background: Homologous recombination repair (HRR) enables fault-free repair of double-stranded DNA breaks. HRR deficiency is predicted to occur in around half of high-grade serous ovarian carcinomas. Ovarian cancers harbouring HRR deficiency typically exhibit sensitivity to poly-ADP ribose polymerase inhibitors (PARPi). Current guidelines recommend a range of approaches for genetic testing to identify predictors of sensitivity to PARPi in ovarian cancer and to identify genetic predisposition.Design: To establish a European-wide consensus for genetic testing (including the genetic care pathway), decision making and clinical management of patients with recently diagnosed advanced ovarian cancer, and the validity of biomarkers to predict the effectiveness of PARPi in the first-line setting. The collaborative European experts' consensus group consisted of a steering committee (n = 14) and contributors (n = 84). A (modified) Delphi process was used to establish consensus statements based on a systematic literature search, conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines.Results: A consensus was reached on 34 statements amongst 98 caregivers (including oncologists, pathologists, clinical geneticists, genetic researchers, and patient advocates). The statements concentrated on (i) the value of testing for BRCA1/2 mutations and HRR deficiency testing, including when and whom to test; (ii) the importance of developing new and better HRR deficiency tests; (iii) the importance of germline non-BRCA HRR and mismatch repair gene mutations for predicting familial risk, but not for predicting sensitivity to PARPi, in the first-line setting; (iv) who should be able to inform patients about genetic testing, and what training and education should these caregivers receive.Conclusion: These consensus recommendations, from a multidisciplinary panel of experts from across Europe, provide clear guidance on the use of BRCA and HRR deficiency testing for recently diagnosed patients with advanced ovarian cancer.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Nyckelord

BRCA1/2; PARP inhibition; genetic counselling; homologous recombination deficiency; mainstream genetic testing; ovarian cancer

Publikations- och innehållstyp

ref (ämneskategori)
for (ämneskategori)

Hitta via bibliotek

Annals of Oncology (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

1 av 1
Föregående post
Nästa post
Till träfflistan

Hitta mer i SwePub

Av författaren/redakt...: Vergote, I.; González-Martín, ...; Ray-Coquard, I.; Harter, P.; Colombo, N.; Pujol, P.; visa fler...; Lorusso, D.; Mirza, M.R.; Brasiuniene, B.; Madry, R.; Brenton, J.D.; Ausems, M.G.E.M.; Büttner, R.; Lambrechts, D.; visa färre...

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Cancer och onkol ...

Artiklar i publikationen: Annals of Oncolo ...

Av lärosätet: Linköpings universitet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se